{"id":3844,"date":"2026-10-22T09:00:00","date_gmt":"2026-10-22T13:00:00","guid":{"rendered":"https:\/\/www.insilens.com\/?p=3844"},"modified":"2026-10-22T20:27:07","modified_gmt":"2026-10-23T00:27:07","slug":"multiomic-model-predicts-induction-mrd-in-myeloma-cohort","status":"publish","type":"post","link":"https:\/\/www.insilens.com\/?p=3844","title":{"rendered":"Multiomic Model Predicts Induction MRD in Myeloma Cohort"},"content":{"rendered":"

\"\"<\/p>\n

Company<\/strong><\/p>\n

MIDAS study investigators (Nature Medicine)<\/p>\n

Event Type<\/strong><\/p>\n

Peer-reviewed publication<\/p>\n

Modality<\/strong><\/p>\n

Multiomic machine-learning prediction model<\/p>\n

Asset<\/strong><\/p>\n

MIDAS multimodal MRD classifier<\/p>\n

Target<\/strong><\/p>\n

Not applicable<\/p>\n

Disease Area<\/strong><\/p>\n

Newly diagnosed multiple myeloma<\/p>\n

Summary<\/h4>\n

An online-first peer-reviewed Nature Medicine study links tumor genomic, transcriptomic and epigenomic states to minimal residual disease after Isa-KRd induction in newly diagnosed myeloma. Its AUC of 0.77 supports biological stratification, not clinical decision readiness.<\/p>\n

Published online 19 October, the MIDAS study profiled 423 pretreatment tumor samples from patients receiving isatuximab, carfilzomib, lenalidomide and dexamethasone. MRD outcomes differed across expression groups; transcriptomic associations were checked in CASSIOPEIA. Driver and genomic-instability findings were compared with three external cohorts totaling 1,451 cases. A multimodal random-forest model predicted postinduction MRD with AUC 0.77.<\/p>\n

Deep Analysis<\/h4>\n

The study integrates multiple disease layers and tests several biological findings externally, reducing the chance that every association is cohort-specific. Yet external validation of selected features is not the same as prospective validation of the locked multimodal classifier. MRD after one induction regimen is an intermediate response marker; no trial assigned therapy on model output or showed improved survival. Tissue sampling, assay reproducibility, inter-laboratory calibration and cost constrain deployment. Regimen specificity matters because other quadruplets and maintenance strategies alter selection pressures.<\/p>\n

Company and Product Background<\/h4>\n

Multiple myeloma is a plasma-cell malignancy with heterogeneous genomic drivers and microenvironmental states. MRD assays detect residual malignant cells after treatment and correlate with prognosis. Isa-KRd combines anti-CD38 antibody, proteasome inhibition, an immunomodulatory agent and dexamethasone.<\/p>\n

Signal Extraction<\/h4>\n
    \n
  • Interpretation A:<\/strong> the model captures treatment-relevant myeloma states missed by clinical risk and may guide future risk-adapted trials.<\/li>\n
  • Interpretation B:<\/strong> it mainly summarizes known proliferative and genetic biology without sufficiently actionable accuracy; AUC 0.77 permits substantial misclassification.<\/li>\n
  • Upgrade<\/strong> with external locked-model calibration and a prospective treatment-assignment study; falsify<\/strong> clinical utility if assignment fails to improve patient outcomes.<\/li>\n<\/ul>\n

    InSilens Take<\/h4>\n

    Inference: the value today is a validated research framework for selecting hypotheses and trial strata. It should not be used to intensify or de-intensify an individual patient\u2019s therapy outside a validated protocol.<\/p>\n

    Signal Assessment<\/h4>\n

    Signal Importance: 4 of 5. Signal Direction: mixed. Confidence in Facts: high. Confidence in Interpretation: moderate.<\/p>\n","protected":false},"excerpt":{"rendered":"

    An online-first peer-reviewed Nature Medicine study links tumor genomic, transcriptomic and epigenomic states to minimal residual disease after Isa-KRd induction in newly diagnosed myeloma. Its AUC of 0.77 supports biological stratification, not clinical decision…<\/p>\n","protected":false},"author":1,"featured_media":3855,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[4],"tags":[1173,1174,1175,30,1176],"class_list":["post-3844","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-technology-modalities","tag-midas","tag-mrd","tag-multiomics","tag-multiple-myeloma","tag-nature-medicine"],"blocksy_meta":[],"_links":{"self":[{"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/posts\/3844","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.insilens.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=3844"}],"version-history":[{"count":1,"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/posts\/3844\/revisions"}],"predecessor-version":[{"id":3864,"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/posts\/3844\/revisions\/3864"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/media\/3855"}],"wp:attachment":[{"href":"https:\/\/www.insilens.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=3844"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.insilens.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=3844"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.insilens.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=3844"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}